OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV
Boehringer Ingelheim Animal Health Canada Inc. contributes to the development of the Centre of Excellence in Veterinary Interventional Medicine and Cardiology at CHUV